JenaValve Appoints Dave Haan as Vice President of Clinical Affairs

JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) System, announced the appointment of Dave Haan as Vice President of Clinical Affairs. Dave will lead the company's clinical affairs strategy, overseeing the continued execution of JenaValve's clinical programs — including the ARTIST randomised controlled trial and the JENA-VAD Registry. His appointment strengthens the company’s clinical leadership during a pivotal period of organisational growth and commercial expansion following the recent FDA approval of the Trilogy THV System for symptomatic, severe aortic regurgitation (ssAR).

Dave brings more than 25 years of executive leadership experience in medical devices, with particular depth in interventional and catheter-based therapies, regulatory strategy, and global trial execution. He has a proven track record of building and scaling clinical organisations, securing regulatory approvals, and advancing evidence generation across complex, high-stakes programs.

Most recently, Dave served as Vice President of Global Clinical Affairs at Danaher's Beckman Coulter Diagnostics, where he led the integration of multiple operating companies into a unified Clinical Centre of Excellence, delivering more than 50 regulatory approvals across the FDA, EU, and NMPA. Before that, Dave held clinical and product development leadership roles at Stryker Neurovascular, where he built and scaled a global clinical organisation, secured FDA IDE and PMA approvals through large-scale clinical trials, and drove industry collaboration through active participation at MDIC. Dave holds a Master of Science in Materials Science and Engineering and a Bachelor of Science from Rutgers University, an MBA from Santa Clara University's Leavey School of Business, and holds a PMP certification.

"Dave's appointment comes at a defining moment for JenaValve," said Duane Pinto, MD, MPH, Chief Medical Officer of JenaValve. "With commercial approval behind us, we look forward to the future of TAVR in AR. As such, Dave is a clinical affairs leader with a strategic vision and operational depth that matches the scale of our ambitions. His record of successfully delivering on complex global programs and regulatory approvals across multiple jurisdictions makes him exactly the right person to lead our program. I look forward to partnering closely with him as we generate the evidence that will bring TAVR with the Trilogy System to the broadest group of patients suffering from AR."

"I am thrilled to join JenaValve at such a pivotal moment in the company's evolution," said Dave Haan, Vice President of Clinical Affairs at JenaValve. "The clinical evidence supporting the Trilogy System is compelling, and the opportunity to lead the next phase of evidence generation, including the ARTIST trial, is an incredible privilege. I look forward to working alongside the talented JenaValve team to advance the science and ultimately expand access to life-changing treatment for patients with AR."